September 27, 2019
Takara Holdings Inc.
Notice Regarding Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV from Takara Bio Inc., a Consolidated Subsidiary of Takara Holdings
Takara Bio Inc. (The First Section of Tokyo Stock Exchange, securities code number: 4974), a consolidated subsidiary of the Company, today issued a news release entitled “Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV”. For details, please refer to the disclosure materials of Takara Bio.
This decision has less impact on the current fiscal year’s financial forecast.
